1. |
Cushley LN, Quinn NB, Blows P, et al. The integration of diabetic eye screening into hemodialysis units in Northern Ireland[J]. Kidney360, 2022, 3(9): 1542-1544. DOI: 10.34067/KID.0001802022.
|
2. |
Silva PS, Marcus DM, Liu D, et al. Association of ultra-widefield fluorescein angiography-identified retinal nonperfusion and the risk of diabetic retinopathy worsening over time[J]. JAMA Ophthalmol, 2022, 140(10): 936-945. DOI: 10.1001/jamaophthalmol.2022.3130.
|
3. |
Vujosevic S, Aldington SJ, Silva P, et al. Screening for diabetic retinopathy: new perspectives and challenges[J]. Lancet Diabetes Endocrinol, 2020, 8(4): 337-347. DOI: 10.1016/S2213-8587(19)30411-5.
|
4. |
Wei J, Wang B, Shen FJ, et al. Diagnostic value of triglyceride and cystatin C ratio in diabetic kidney disease: a retrospective and prospective cohort study based on renal biopsy[J]. BMC Nephrol, 2022, 23(1): 270. DOI: 10.1186/s12882-022-02888-3.
|
5. |
Benoit SW, Ciccia EA, Devarajan P. Cystatin C as a biomarker of chronic kidney disease: latest developments[J]. Expert Rev Mol Diagn, 2020, 20(10): 1019-1026. DOI: 10.1080/14737159.2020.1768849.
|
6. |
Zhou J, Song S, Zhang Y, et al. OCT-based biomarkers are associated with systemic inflammation in patients with treatment-naïve diabetic macular edema[J]. Ophthalmol Ther, 2022, 11(6): 2153-2167. DOI: 10.1007/s40123-022-00576-x.
|
7. |
Gurudas S, Frudd K, Maheshwari JJ, et al. Multicenter evaluation of diagnostic circulating biomarkers to detect sight-threatening diabetic retinopathy[J]. JAMA Ophthalmol, 2022, 140(6): 587-597. DOI: 10.1001/jamaophthalmol.2022.1175.
|
8. |
ElSayed NA, Aleppo G, Aroda VR, et al. Classification and diagnosis of diabetes: standards of care in diabetes-2023[J]. Diabetes Care, 2023, 46(Suppl 1): S19-40. DOI: 10.2337/dc23-S002.
|
9. |
Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
|
10. |
Mushtaq N, Hussain S, Zhang S, et al. Molecular characterization of alterations in the intestinal microbiota of patients with grade 3 hypertension[J]. Int J Mol Med, 2019, 44(2): 513-522. DOI: 10.3892/ijmm.2019.4235.
|
11. |
Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report[J]. Kidney Int, 2011, 80(1): 17-28. DOI: 10.1038/ki.2010.483.
|
12. |
Choi MG, Kim JT. Strong correlation of renal function with choroidal thickness in patients with type 2 diabetes: retrospective cross-sectional study[J]. J Clin Med, 2020, 9(7): 2171. DOI: 10.3390/jcm9072171.
|
13. |
Sun Q, Jing Y, Zhang B, et al. The risk factors for diabetic retinopathy in a Chinese population: a cross- sectional study[J/OL]. J Diabetes Res, 2021, 2021: 5340453[2021-01-28]. https://pubmed.ncbi.nlm.nih.gov/33575359/. DOI: 10.1155/2021/5340453.
|
14. |
Mo R, Shi R, Hu Y, et al. Nomogram-based prediction of the risk of diabetic retinopathy: a retrospective- study[J/OL]. J Diabetes Res, 2020, 2020: 7261047[2020-06-07]. https://pubmed.ncbi.nlm.nih.gov/32587869/. DOI: 10.1155/2020/7261047.
|
15. |
Huang S, Zhang S, Wang J, et al. Correlation between serum cystatin C level and retinal blood flow in patients with essential hypertension[J]. Ophthalmic Res, 2022, 65(3): 335-341. DOI: 10.1159/000522219.
|
16. |
Inker LA, Eneanya ND, Coresh J, et al. Chronic kidney disease epidemiology collaboration. new creatinine- and cystatin c-based equations to estimate GFR without race[J]. N Engl J Med, 2021, 385(19): 1737-1749. DOI: 10.1056/NEJMoa2102953.
|
17. |
Ebert N, Bevc S, Bökenkamp A, et al. Assessment of kidney function: clinical indications for measured GFR[J]. Clin Kidney J, 2021, 14(8): 1861-1870. DOI: 10.1093/ckj/sfab042.
|
18. |
Omaygenç MO, Özcan ÖU, Çakal B, et al. Cystatin C and uncontrolled hypertension[J]. Anatol J Cardiol, 2020, 24(5): 309-315. DOI: 10.14744/AnatolJCardiol.2020.78974.
|
19. |
Zhao M, Che Q, Zhang Y, et al. Expression and clinical significance of serum cystatin C in patients with hypertension and coronary heart disease[J/OL]. Medicine (Baltimore), 2020, 99(22): e20029[2020-05-29]. https://pubmed.ncbi.nlm.nih.gov/32481372/. DOI: 10.1097/MD.0000000000020029.
|
20. |
Sahakyan K, Klein BE, Lee KE, et al. Serum cystatin C and the incidence of hypertension in type 1 diabetes mellitus[J]. Am J Hypertens, 2011, 24(1): 59-63. DOI: 10.1038/ajh.2010.215.
|
21. |
Ma J, Wu Z, Zha X, et al. The combined effect of serum cystatin C and dyslipidemia on hypertension in a large health check-up population in China[J]. Clin Exp Hypertens, 2019, 41(8): 702-707. DOI: 10.1080/10641963.2018.1545845.
|
22. |
Shankar A, Teppala S. Relationship between serum cystatin C and hypertension among US adults without clinically recognized chronic kidney disease[J]. J Am Soc Hypertens, 2011, 5(5): 378-384. DOI: 10.1016/j.jash.2011.03.003.
|